Overall, CeO2-NPs represent a promising disease-modifying nanomedicine for AMD that extends beyond conventional antioxidant supplementation and anti-VEGF therapy, yet further studies are required to clarify optimal formulations, therapeutic timing, and translational safety to fully harness their regenerative and neuroprotective potential. Here, VEGFA is linked to age-related macular degeneration.